# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anteo Diagnostics Limited	
ABN	75 070 028 625	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr John (Jack) Hamilton
Date of last notice	6 June 2019

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder)	Jackjen Pty Ltd <atf fund="" hamilton="" j="" superannuation=""></atf>	
Note: Provide details of the circumstances giving rise to the relevant interest.	(Dr Hamilton is a beneficiary of the super fund)	
Date of change	31 March 2020	
No. of securities held prior to change	13,823,636 Ordinary Shares 5,886,818 Quoted Options (\$0.02 @ 6-Dec-20)	
Class	Ordinary Shares Quoted Options (\$0.03 @ 31-Mar-23)	
Number acquired	10,308,139 Ordinary Shares 5,154,069 Quoted Options (\$0.03 @ 31-Mar-23)	
Number disposed	Nil	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Shares issued at \$0.015 each; options issued for nil consideration	

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	24,131,775 Ordinary Shares	
	5,886,818 Quoted Options (\$0.02 @ 6-Dec-20)	
	5,154,069 Quoted Options (\$0.03 @ 31-Mar-23)	
Nature of change	Participation in the Company's Renounceable Rights Issue and partial underwriting (\$125,000) of the Rights	
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

On behalf of the Board DP Cornish, Company Secretary 3 April 2020

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anteo Diagnostics Limited
ABN	75 070 028 625

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Geoff Cumming
Date of last notice	6 June 2019

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect holdings held by <b>Bond Street Custodians Limited</b> on behalf of the Jamelys Superannuation Fund, for which Mr Cumming is a beneficiary
Date of change	31 March 2020
No. of securities held prior to change	25,769,696 Ordinary Shares 1,468,182 Quoted Options (\$0.02 @ 6-Dec-20)
Class	Ordinary Shares Quoted Options (\$0.03 @ 31-Mar-23)
Number acquired	3,681,385 Ordinary Shares 1,840,692 Quoted Options (\$0.03 @ 31-Mar-23)
Number disposed	Nil
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Shares issued at \$0.015 each; options issued for nil consideration

+ See chapter 19 for defined terms.

No. of securities held after change	29,451,081 Ordinary Shares 1,468,182 Quoted Options (\$0.02 @ 6-Dec-20)
	1,840,692 Quoted Options (\$0.03 @ 31-Mar-23)
Nature of change	Participation in the Company's Renounceable Rights Issue
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

On behalf of the Board DP Cornish, Company Secretary 3 April 2020

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anteo Diagnostics Limited	
ABN	75 070 028 625	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Matthew Sanderson
Date of last notice	6 June 2019

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Tagrich Capital Pty Ltd <tagrich a="" c="" capital="" f="" s=""> (Mr Sanderson is a director, shareholder and beneficiary of the fund)  Twinvest Holdings Pty Ltd (Mr Sanderson is a director and shareholder of the company)  Citicorp Nominees Pty Limited (Broker account of Twinvest, of which Mr Sanderson is a director and shareholder of the company)  Twinfitness Pty Ltd (Mr Sanderson is a director and shareholder of the company)</tagrich>
Date of change	31 March 2020

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held prior to change	
Tagrich Capital Pty Ltd	1,260,000 Ordinary Shares
	105,000 Quoted Options (\$0.02 @ 6-Dec-20)
Twinvest Holdings Pty Ltd	5,155,400 Ordinary Shares
	2,512,950 Quoted Options (\$0.02 @ 6-Dec-20)
Citicorp Nominees Pty Ltd	180,000 Ordinary Shares
Twinfitness Pty Ltd	126,000 Ordinary Shares
	10,500 Quoted Options (\$0.02 @ 6-Dec-20)
Total	6,721,400 Ordinary Shares
	2,628,450 Quoted Options (\$0.02 @ 6-Dec-20)
Class	Ordinary Shares
	Quoted Options (\$0.03 @ 31-Mar-23)
Number acquired	
Tagrich Capital Pty Ltd	180,000 Ordinary Shares
	90,000 Quoted Options (\$0.03 @ 31-Mar-23)
Twinvest Holdings Pty Ltd	736,485 Ordinary Shares
	368,242 Quoted Options (\$0.03 @ 31-Mar-23)
Twinfitness Pty Ltd	18,000 Ordinary Shares
	9,000 Quoted Options (\$0.03 @ 31-Mar-23)
Number disposed	Nil
Value/Consideration	Shares issued at \$0.015 each; options issued for nil consideration
Note: If consideration is non-cash, provide details and estimated valuation	Consideration
No. of securities held after change	
Tagrich Capital Pty Ltd	1,440,000 Ordinary Shares
	105,000 Quoted Options (\$0.02 @ 6-Dec-20)
	90,000 Quoted Options (\$0.03 @ 31-Mar-23)
Twinvest Holdings Pty Ltd	5,891,885 Ordinary Shares
	2,512,950 Quoted Options (\$0.02 @ 6-Dec-20)
	368,242 Quoted Options (\$0.03 @ 31-Mar-23)
Citicorp Nominees Pty Ltd	180,000 Ordinary Shares
Twinfitness Pty Ltd	144,000 Ordinary Shares
	10,500 Quoted Options (\$0.02 @ 6-Dec-20)
	9,000 Quoted Options (\$0.03 @ 31-Mar-23)

<sup>+</sup> See chapter 19 for defined terms.

Total	7,655,885 2,628,450 467,242	Ordinary Shares Quoted Options (\$0.02 @ 6-Dec-20) Quoted Options (\$0.03 @ 31-Mar-23)
Nature of change  Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participatio Issue	n in the Company's Renounceable Rights

## Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

#### Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

On behalf of the Board DP Cornish, Company Secretary 3 April 2020

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anteo Diagnostics Limited	
ABN	75 070 028 625	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Parker
Date of last notice	1 October 2019

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	31 March 2020
No. of securities held prior to change	Nil
Class	Ordinary Shares Quoted Options (\$0.03 @ 31-Mar-23)
Number acquired	1,000,000 Ordinary Shares 500,000 Quoted Options (\$0.03 @ 31-Mar-23)
Number disposed	Nil
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Shares issued at \$0.015 each; options issued for nil consideration

+ See chapter 19 for defined terms.

No. of securities held after change	1,000,000 Ordinary Shares 500,000 Quoted Options (\$0.03 @ 31-Mar-23)
Nature of change  Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Partial underwriting (\$15,000) of the Company's Renounceable Rights Issue

## Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

#### Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

On behalf of the Board DP Cornish, Company Secretary 3 April 2020

<sup>+</sup> See chapter 19 for defined terms.